---
schema_version: "secwatch.filing_event.v1"
accession: "0001860742-25-000021"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:43:26.942213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb Q3 revenue $1.28B (+7% YoY); narrows FY adjusted EBITDA guidance to $870M-$910M

## Summary
- Revenue $1.281B, up 7% reported (6% constant currency); Vision Care +8%, Surgical +4%, Pharmaceuticals +8%.
- GAAP net loss $28M ($0.08 loss per share) vs net income $4M ($0.01 EPS) in Q3 2024.
- Adjusted EBITDA excluding acquired IPR&D $243M, up from $227M; adjusted EPS excl. IPR&D $0.18 vs $0.17.
- FY 2025 revenue guidance reaffirmed at $5.05B-$5.15B; adjusted EBITDA guidance low end raised $10M to $870M-$910M.
- Cash from operations $137M vs $154M; CEO cites pipeline and investor day as upcoming catalysts.

## SEC filing metadata
- accession: 0001860742-25-000021
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000186074225000021/0001860742-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000186074225000021/blco-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860742-25-000021
- JSON: https://secwatch.observer/filing/0001860742-25-000021.json
- Plain text: https://secwatch.observer/filing/0001860742-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.